• Special Issue Topic

    Molecular Targeted Therapy for Cancer

    Submission Deadline: August 31, 2023

    Guest Editors

    Prof. Wei-Lin Jin E-Mail

    Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, China

    Research Keywords: brain tumors; cancer stem cells; epigenetics in cancer biology; cancer immunotherapy

    Prof. Xing-Chun Gao  E-Mail

    Associate Research Scientist, Yale university, New Haven, CT 06511, USA

    About the Special Issue

    Cancer is a significant disease that seriously affects human health and remains one of the most challenging diseases worldwide. With the growth of human life and the development of detection technology, the number of cancer patients has increased yearly. In recent decades, cancer therapy has become more personalized, efforts have been made toward drug development and novel therapeutic methods.  Discovery and identification of novel molecules involved in cancer progression allow for a complete understanding of the biology behind cancer, and corresponding therapies against these molecular targets can provide more options for cancer treatment. Many molecular-targeted therapies are being tested in pre-clinical and clinical studies.
    Given the complexity of this topic and its impact on clinical practice and public health, ETAT is launching a Special Issue entitled “Molecular Targeted Therapy for Cancer” to provide a platform for active discussion and summarizing current knowledge of new perspectives on developing novel molecular targeted therapeutic approaches and biomarkers for cancer. We welcome high-quality original research articles, brief reports, as well as opinion, hypothesis, and review articles, and especially encourage submissions from early-career scientists.

    Call for Papers

    Published Articles

    Open Access
    Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective
    In recent times, there have been notable advancements in comprehending the potential anti-cancer effects of chrysin (CH), a naturally occurring flavonoid compound found abundantly in various plant s [...] Read more.
    Abhilasha Sood ... Manoj Kumar
    Published: May 23, 2024 Explor Target Antitumor Ther. 2024;5:477–494
    DOI: https://doi.org/10.37349/etat.2024.00230
    Times Cited: 0
    Open Access
    The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates
    Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancers with high mortality rate. Among its various etiological factors, one of the major risk factors for HCC is a chronic [...] Read more.
    Agustiningsih Agustiningsih ... Caecilia Sukowati
    Published: February 20, 2024 Explor Target Antitumor Ther. 2024;5:120–134
    DOI: https://doi.org/10.37349/etat.2024.00209
    Times Cited: 0
    Open Access
    Original Article
    Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer
    Aim: It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (ARneg), androgen-independent (AI) prostate cancer, whic [...] Read more.
    Vignesh Sivaganesh, Bela Peethambaran
    Published: December 20, 2023 Explor Target Antitumor Ther. 2023;4:1188–1209
    DOI: https://doi.org/10.37349/etat.2023.00192
    Times Cited: 0